A chronic inflammatory skin disease, hidradenitis suppurativa (HS), which affects millions of Americans, is seeing new therapeutic hope with the emergence of JAK inhibitors and the established success of biologic drugs.
HS causes painful lumps to form deep beneath the skin, typically around the armpits and groin. These lesions can rupture into weeping sores and tunnels, leading to permanent scarring. For many, like Laurelle-Maria Sterling, who has lived with the condition since her teens, the pain and recurring nature of HS have significantly impacted their quality of life. Sterling described years of agonizing flare-ups and numerous courses of antibiotics that failed to provide lasting relief.
"The pain from healing is better than the pain from the condition," Sterling, now 32, said. "But it didn't stop flare-ups in other areas."
Advances in Treatment
Four years ago, Sterling began treatment with adalimumab, a biologic drug used for conditions like rheumatoid arthritis and psoriasis. This medication works by blocking parts of the immune response responsible for inflammation, significantly reducing the severity of her flare-ups.
Now, experts believe JAK inhibitors, a class of anti-inflammatory medications already used for diseases such as rheumatoid arthritis and eczema, could offer further relief for HS patients. Research suggests these drugs can treat HS by blocking inflammatory signals at a cellular level. Dermatologists are becoming more proactive in offering these treatments at earlier stages of the disease.
Dr. Abirami Pararajasingam, a dermatologist, highlighted the importance of early intervention, noting that chronic inflammation from HS is a risk factor for other health issues, including heart disease and stroke. "That's why early intervention is key in tackling it," she stated.
Understanding Hidradenitis Suppurativa
Once considered rare, HS is now believed to affect as many as one in 100 people, though a significant number remain undiagnosed. The condition is driven by an overactive immune response that causes inflammation around blocked hair follicles. Its severity varies greatly, from minor blackheads to severe lesions that take years to heal.
Women are more commonly affected than men, with symptoms often beginning in adolescence or early adulthood. The disease can be easily mistaken for other skin issues, and the lack of a definitive diagnostic test can lead to years of delayed diagnosis. This diagnostic delay means many patients suffer in silence as irreversible skin damage occurs.
"If HS is diagnosed and treated early, much of the worst damage can be avoided," said Dr. Beibei Du-Harpur, a clinical lecturer in dermatology at King's College London. "People are just sitting at home coping as that damage is occurring because they don't understand what's happening. This lack of awareness is also a huge issue among clinicians."
While the exact causes of HS are not fully understood, genetics are thought to play a role, with about a third of patients reporting a family history. Smoking and obesity are also strongly linked to the disease, potentially by encouraging blocked hair follicles or creating a state of chronic inflammation.
Promising Research
Biologic drugs like adalimumab have transformed treatment for severe HS by targeting specific immune system proteins. For patients who do not respond adequately to existing treatments, JAK inhibitors are showing promise. A study involving the experimental JAK inhibitor povorcitinib demonstrated a significant reduction in inflammatory nodules and abscesses in HS patients, offering a potential new weapon against this debilitating condition.